

Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Setegis - tablets:
1 tab. contains terazosin 1, 2, 5 and 10 mg; 30 pieces per pack.
Setegis has an alpha-adrenolytic effect. By blocking the postsynaptic alpha1-adrenergic receptors of the smooth muscles of the triangle and bladder neck, the proximal part of the urethra and the prostate gland, reduces the resistance to urine flow and normalizes urination in patients with BPH.
BPH, arterial hypertension (as monotherapy or as part of combination therapy).
Hypersensitivity to terazosin or other alpha adrenoceptor blocking agents.
In pregnancy and lactation, Setegis is used with great caution, only after a careful comparison of the ratio between the risk to the fetus or child and the positive effect to the mother.
At the beginning of treatment, the “first dose phenomenon” may occur - orthostatic hypotension until fainting. In addition, when treating Setegis, dizziness, headache, asthenia, drowsiness, palpitations, nausea, nasal congestion, blurred vision, peripheral edema, weight gain may occur; rarely - postural hypotension, tachycardia, hemodilution phenomena.
The drug should be taken orally, Setegis pills should be taken whole, without chewing, regardless of the meal.
BPH: initial dose - 1 mg 1 time per day, supporting - 5-10 mg 1 time per day, the maximum daily dose - 20 mg.
In a dry, dark place at a temperature of no higher than 20 ° C.